Arkema S.A. (ARKAY)
:ARKAY
US Market
Advertisement

Arkema SA (ARKAY) AI Stock Analysis

Compare
36 Followers

Top Page

ARKAY

Arkema SA

(OTC:ARKAY)

Select Model
Select Model
Select Model
Neutral 61 (OpenAI - 4o)
Rating:61Neutral
Price Target:
$60.00
▼(-1.67% Downside)
Arkema's overall stock score is primarily impacted by its financial performance challenges, including declining revenue growth and profitability margins. Technical analysis indicates a bearish trend, adding to the cautious outlook. However, the stock's valuation is reasonable, with a strong dividend yield providing some support. The earnings call reflects strategic efforts but also highlights significant market challenges.

Arkema SA (ARKAY) vs. SPDR S&P 500 ETF (SPY)

Arkema SA Business Overview & Revenue Model

Company DescriptionArkema SA (ARKAY) is a global leader in specialty chemicals and advanced materials, headquartered in France. The company operates through three main segments: High Performance Materials, Industrial Specialties, and Coating Solutions. Arkema's core products include polymers, additives, and coatings that cater to a diverse range of industries, including automotive, construction, electronics, and healthcare. With a strong emphasis on innovation and sustainability, Arkema is committed to developing high-performance solutions that meet the evolving needs of its customers while minimizing environmental impact.
How the Company Makes MoneyArkema generates revenue primarily through the sale of its specialty chemicals and materials across various industries. The company has established key revenue streams through its three main segments, with High Performance Materials being the largest contributor, driven by demand for advanced polymers and composites. Industrial Specialties and Coating Solutions also play significant roles, with products that include adhesives, sealants, and specialty coatings. Additionally, Arkema engages in strategic partnerships and collaborations to enhance its product offerings and expand its market reach, which further contributes to its earnings. The company's focus on innovation allows it to command premium pricing for its specialized products, thereby increasing profitability.

Arkema SA Earnings Call Summary

Earnings Call Date:Nov 07, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Feb 26, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted Arkema's strategic expansions and successful cost management, but these were overshadowed by weaker-than-expected market conditions in the U.S. and Europe, leading to significant declines in EBITDA and revenue. The company is taking steps to mitigate these challenges, but the outlook remains cautious.
Q3-2025 Updates
Positive Updates
Major Project Update
Arkema's major project is expected to bring in EUR 60 million additional EBITDA in 2025 versus 2024, up from the initially estimated EUR 50 million due to strong momentum in PVDF for batteries and new generation fluorospecialties.
Expansion in Advanced Electronics
Arkema announces expansion in the advanced electronics market, specifically data centers, with expected significant growth prospects, though starting from a low base.
Successful Cost-Cutting Initiatives
Arkema is on track to deliver EUR 100 million of fixed and variable cost savings by year-end. This includes efforts to offset inflation in 2025 and 2026.
Solid Cash Flow and Reduced Debt
Arkema delivered EUR 207 million recurring cash flow, up compared to last year despite lower earnings, and reduced CapEx next year to EUR 600 million while maintaining a robust balance sheet.
Negative Updates
Weaker-than-Expected U.S. Market
Arkema faced lower demand in the U.S. over the summer, attributed to ongoing uncertainty around tariffs and supply chain frictions, impacting overall performance.
EBITDA Decline
Despite the cost-cutting efforts, Arkema's EBITDA was down to EUR 310 million, with segments like Coatings and Intermediates experiencing significant volatility.
Revenue Decline
Q3 sales were down 8.6% year-on-year, impacted by a negative 3.9% currency effect and a 2.5% volume decrease due to weak demand in the U.S. and Europe.
Reduced Guidance
Arkema's updated guidance reflects a cautious outlook with an expected EBITDA of between EUR 1.25 billion and EUR 1.3 billion in 2025, lower than previous forecasts.
Company Guidance
During Arkema's Third Quarter 2025 Results and Outlook Conference Call, the company provided updated guidance amidst a challenging macroeconomic environment. Despite a weaker-than-expected U.S. market and low demand in Europe, Arkema reported substantial growth in several key markets, with sales up by 20% in batteries, sports, 3D printing, healthcare, and new generation fluorospecialties. Arkema increased its expected EBITDA contribution from major projects to EUR 60 million for 2025, up from the previously forecasted EUR 50 million. Additionally, the company is on track to achieve EUR 100 million in fixed and variable cost savings by the end of the year and plans to reduce capital expenditures to EUR 600 million in 2026. Arkema's Q3 sales were EUR 2.2 billion, representing an 8.6% year-on-year decline, while Q3 EBITDA stood at EUR 310 million. The company anticipates an EBITDA range of EUR 1.25 billion to EUR 1.3 billion for 2025.

Arkema SA Financial Statement Overview

Summary
Arkema SA faces challenges with declining revenue growth and profitability margins. The balance sheet remains stable with a reasonable debt level, but cash flow constraints could pose risks. The company needs to focus on improving revenue growth and managing costs to enhance profitability and cash flow generation.
Income Statement
65
Positive
Arkema SA's income statement shows a decline in revenue growth with a negative trend in the TTM period. The gross profit margin has slightly decreased over time, indicating pressure on cost management. Net profit margin has also decreased, reflecting challenges in maintaining profitability. However, the company maintains a stable EBIT and EBITDA margin, suggesting operational efficiency.
Balance Sheet
70
Positive
The balance sheet reflects a moderate debt-to-equity ratio, indicating a balanced approach to leveraging. The return on equity has decreased over the years, showing a decline in profitability relative to shareholder equity. However, the equity ratio remains strong, suggesting financial stability and a solid asset base.
Cash Flow
60
Neutral
Cash flow analysis reveals a decline in free cash flow growth, which could impact future investments and dividend payouts. The operating cash flow to net income ratio indicates that cash generation from operations is healthy, but the free cash flow to net income ratio has decreased, highlighting potential liquidity constraints.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue9.44B9.54B9.51B11.55B9.52B7.88B
Gross Profit1.80B1.94B1.96B2.58B2.14B1.55B
EBITDA1.10B1.31B1.33B1.81B1.87B1.22B
Net Income226.00M354.00M418.00M965.00M1.31B332.00M
Balance Sheet
Total Assets13.92B15.21B14.52B13.51B12.30B10.71B
Cash, Cash Equivalents and Short-Term Investments1.31B2.01B2.04B1.59B2.29B1.63B
Total Debt3.79B4.55B4.28B3.26B2.76B2.80B
Total Liabilities6.47B7.45B7.06B6.17B5.95B5.48B
Stockholders Equity7.23B7.53B7.20B7.30B6.30B5.19B
Cash Flow
Free Cash Flow222.00M353.00M593.00M766.00M152.00M510.00M
Operating Cash Flow1.02B1.12B1.27B1.50B915.00M1.11B
Investing Cash Flow-900.00M-940.00M-1.35B-2.34B473.00M-458.00M
Financing Cash Flow-964.00M-207.00M516.00M168.00M-652.00M-535.00M

Arkema SA Technical Analysis

Technical Analysis Sentiment
Negative
Last Price61.02
Price Trends
50DMA
62.64
Negative
100DMA
67.63
Negative
200DMA
71.29
Negative
Market Momentum
MACD
-0.80
Negative
RSI
52.83
Neutral
STOCH
89.18
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARKAY, the sentiment is Negative. The current price of 61.02 is above the 20-day moving average (MA) of 59.90, below the 50-day MA of 62.64, and below the 200-day MA of 71.29, indicating a neutral trend. The MACD of -0.80 indicates Negative momentum. The RSI at 52.83 is Neutral, neither overbought nor oversold. The STOCH value of 89.18 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARKAY.

Arkema SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
$13.85B20.1724.05%1.93%3.09%12.25%
67
Neutral
$6.95B10.1612.24%5.45%-3.33%-19.59%
67
Neutral
$21.88B17.4016.31%2.85%-12.98%-11.34%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
61
Neutral
$4.52B28.262.19%6.92%-0.85%-56.71%
55
Neutral
$16.08B-2.84%2.53%-3.01%82.30%
51
Neutral
$13.94B-10.44%12.51%-19.65%-157.13%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ARKAY
Arkema SA
61.11
-17.41
-22.17%
EMN
Eastman Chemical
60.94
-35.79
-37.00%
IFF
International Flavors & Fragrances
65.41
-22.05
-25.21%
LYB
LyondellBasell
43.31
-32.77
-43.07%
PPG
PPG Industries
97.49
-22.85
-18.99%
RPM
RPM International
107.47
-26.05
-19.51%

Arkema SA Corporate Events

Arkema Reports Resilient Cash Flow Amid Challenging Q3 2025
Nov 8, 2025

Arkema S.A., a leading player in the specialty chemicals industry, focuses on providing innovative solutions across various sectors, including adhesives, advanced materials, and coating solutions. The company reported a challenging third quarter of 2025, with sales declining by 4.7% at constant exchange rates to €2.2 billion, primarily due to decreased demand in the United States and Europe, although Asia showed resilience. Despite the tough market conditions, Arkema achieved strong cash flow generation, reflecting its operational discipline and strategic focus on high-growth markets such as batteries, sports, and healthcare. Key financial metrics showed a decrease in EBITDA to €310 million from €407 million in the previous year, with an EBITDA margin of 14.2%. The company also reported an adjusted net income of €78 million, down from €168 million in Q3 2024. Arkema’s strategic initiatives include cost-cutting efforts to offset fixed costs inflation and a reduction in capital expenditure, aiming for an EBITDA between €1.25 billion and €1.3 billion for the full year 2025. Looking forward, Arkema remains committed to its growth strategy, leveraging its technological platforms and innovation to capture opportunities driven by global megatrends, while managing the current economic and geopolitical challenges.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 08, 2025